Your browser doesn't support javascript.
loading
Recent advance in influencing factors of non-response to Infliximab therapy in children with inflammatory bowel disease / 中国小儿急救医学
Chinese Pediatric Emergency Medicine ; (12): 208-211, 2023.
Article Dans Chinois | WPRIM | ID: wpr-990504
ABSTRACT
Inflammatory bowel disease(IBD)is a group chronic inflammatory gastrointestinal diseases with unknown etiology, which includes Crohn′s disease, ulcerative colitis and indeterminate colitis.The number of pediatric IBD patients increases year by year and the disease causes a huge burden on patients, families and society.Infliximab(IFX) is an effective and important drug, but more and more patients don′t respense to it.The reason for non-respense is complex and unclear.This review discussed the factors that may cause failure to respond to IFX, in order to find a suitable method to improve the therapeutic effect of IFX on children with IBD.

Texte intégral: Disponible Indice: WPRIM (Pacifique occidental) langue: Chinois Texte intégral: Chinese Pediatric Emergency Medicine Année: 2023 Type: Article

Documents relatifs à ce sujet

MEDLINE

...
LILACS

LIS

Texte intégral: Disponible Indice: WPRIM (Pacifique occidental) langue: Chinois Texte intégral: Chinese Pediatric Emergency Medicine Année: 2023 Type: Article